On Sept. 25, the FDA approved Eli Lilly’s once-daily Olumiant (baricitinib) for severe alopecia areata in patients 12 and older, extending its use beyond adults. Its boxed warnings include serious infections, death, cancer, major heart events and blood clots.
Lilly reported Q2 2026 revenue of $22.97 billion, up 48% year over year, and raised its full-year guidance to $85 billion–$87 billion. Mounjaro and Zepbound generated $9.94 billion and $4.93 billion, respectively, and together accounted for more than 64% of quarterly revenue.
Lilly’s realized prices fell 13% globally in Q2, including a 36% drop outside the U.S. The article attributes the overseas decline to reimbursement adjustments in international markets such as China.
